Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Syed Hasan

Neurology Riverdale, GA Medical Doctor

NPI 1972605418 CMS profile 316071

189 Medical Way Ste C, Riverdale, GA 30274

Open in the dashboard

General payments

$11,622

601 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Syed Hasan of Riverdale, GA is reported in the CMS Open Payments database as having received $11,622 across 601 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,635 170
2024 General $1,639 91
2023 General $1,030 54
2022 General $2,250 116
2021 General $1,997 102
2020 General $731 46
2019 General $340 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Syed Hasan
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Syed Hasan were reported at $3,635. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Syed Hasan Neurology median Middle half National median
2019 $340 $474 $118–$2,177 $163
2020 $731 $367 $82–$2,309 $114
2021 $1,997 $438 $104–$2,547 $132
2022 $2,250 $442 $103–$2,388 $149
2023 $1,030 $464 $119–$2,312 $160
2024 $1,639 $468 $119–$2,323 $164
2025 $3,635 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. UCB, Inc. $951 61 payments
  2. Jazz Pharmaceuticals Inc. $794 43 payments
  3. Sunovion Pharmaceuticals Inc. $764 48 payments
  4. AbbVie, Inc. $648 45 payments
  5. Biogen, Inc. $598 35 payments
  6. Teva Pharmaceuticals USA, Inc. $508 20 payments
  7. Amgen Inc. $451 21 payments
  8. Novartis Pharmaceuticals Corporation $448 25 payments
  9. SK Life Science, Inc. $416 25 payments
  10. Axsome Therapeutics, Inc. $386 15 payments
  11. Other $5,658 263 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,413 597 payments
  2. Education $210 4 payments
Products named General payments · program years 2019–2025
  1. Epidiolex $1,030 56 payments
  2. APTIOM $748 48 payments
  3. Briviact $680 43 payments
  4. UBRELVY $441 30 payments
  5. KESIMPTA $378 21 payments
  6. NUEDEXTA $366 15 payments
  7. NURTEC ODT $354 21 payments
  8. TANLOR $289 7 payments
  9. TYSABRI $271 19 payments
  10. Symbravo $265 9 payments
  11. Other $6,605 340 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 109 drugs

Part D claims

7,293

Median for Neurology: 833

Drug cost

$1,969,705

Median for Neurology: $202,670

Branded share of claims

23.7%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Epidiolex Cannabidiol (Cbd) Brand 63 $457,533
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 17 $364,800
Kesimpta Pen Ofatumumab Brand 22 $272,749
Rebif Rebidose Interferon Beta-1a/Albumin Brand 13 $136,709
Rebif Interferon Beta-1a/Albumin Brand 11 $134,306
Nurtec Odt Rimegepant Sulfate Brand 59 $104,162
Ozempic Semaglutide Brand 82 $95,305
Botox Onabotulinumtoxina Brand 25 $44,307
Qulipta Atogepant Brand 27 $37,227
Emgality Syringe Galcanezumab-Gnlm Brand 12 $26,184

The 10 drugs with the highest cost, of 109 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$67,547

Medicare's payments for the services billed

Medicare patients

256

Average age 72

Services billed

651

173 women, 83 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Diabetes 42%
Chronic kidney disease 39%
Alzheimer's or dementia 30%
Ischemic heart disease 23%
Depression 23%
COPD 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Epidiolex
  • JAZZ PHARMACEUTICALS INC. $269
$269 63 —
KESIMPTA
  • Novartis Pharmaceuticals Corporation $207
$207 22 —
Hizentra
  • CSL Behring $97
$97 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $90
$90 — —
Leqembi
  • Eisai Inc. $45
  • Biogen, Inc. $42
$87 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

601 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record